

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 17 October 2025

Ref: 30774

Requested Information:

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of July, August and September (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st July 2025, they are not classed as a new patient for the purposes of this question.

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]			
Adalimumab [All Biosimilar]			
Etrasimod			
Filgotinib			
Golimumab			
Infliximab [Remicade]			
Infliximab [All Biosimilar]			
Mirikizumab			
Ozanimod			
Risankizumab			
Tofacitinib			
Upadacitinib			
Ustekinumab [Stelara]			
Ustekinumab [All Biosimilar]			
Vedolizumab			

Response:

- 1) Only Homecare prescriptions are currently recorded with an indication therefore the following numbers are those patients treated with the following drugs for Ulcerative Colitis or Crohn's Disease via Homecare only (infusions are not delivered via homecare so will not appear in these indication numbers) during July to September 2025. The overall total column shows all patients given each drug in the time period, not just homecare.

	Crohn's disease	Ulcerative colitis	total overall
Adalimumab [Humira]	6	1	8
Adalimumab [All Biosimilar]	239	62	366
Etrasimod	0	0	0
Filgotinib	0	1	2
Golimumab	0	3	3
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	13	18	131
Mirikizumab	0	0	0
Ozanimod	0	2	2
Risankizumab	15	3	28
Tofacitinib	0	6	7
Upadacitinib	28	25	58
Ustekinumab [Stelara]	5	1	12
Ustekinumab [All Biosimilar]	158	45	239
Vedolizumab	25	100	241

We are unable to tell definitively if a patient is a new patient or not without going through their notes manually, which would take longer than is allowed for an FOI request.

Attachment(s):

No Attachment(s)

Date Response sent: 4 November 2025